CompletedNot Applicable

Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation

China60 participantsStarted 2021-05-06

Plain-language summary

This study aims to evaluate the clinical performance of a novel microRNA-based detection platform, SE-SPTM-PCR, for identifying cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (HSCT). Specifically, the study retrospectively analyzes plasma samples to determine whether hcmv-miR-UL22A-5p can serve as a sensitive and specific biomarker for CMV reactivation. Results will be compared to traditional CMV DNA testing methods.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients who received allogeneic hematopoietic stem cell transplantation (HSCT) Availability of archived plasma samples collected within 100 days post-transplant Documented CMV DNA testing results corresponding to the plasma sample Age ≥ 18 years Exclusion Criteria: Lack of corresponding CMV DNA testing results Inadequate volume or quality of archived plasma sample for analysis Concurrent active infections with other viruses (e.g., EBV, HBV, HCV) at time of plasma collection Patients who received investigational antiviral therapy within 2 weeks prior to sample collection

What they're measuring

Diagnostic performance of SE-SPTM-PCR for detecting CMV reactivation

Timeframe: through study completion, an average of 1 month

Trial details

NCT IDNCT07181330

SponsorTing YANG

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-05-06

View on ClinicalTrials.gov More Cytomegalovirus Infections trials